Trial reportNature medicine2021
Development of a human skin commensal microbe for bacteriotherapy of atopic dermatitis and use in a phase 1 randomized clinical trial.
Trial report in Nature medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 169 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A First in Man Evaluation of the Safety and Efficacy of an Allogeneic Targeted Microbiome Transplant in Adults With Moderate-to-Severe Atopic Dermatitis (ADRN-08)
A Phase 2b, Double-Blind, Randomized, Placebo-Controlled Trial of Cardamom and Topical Roseomonas in Atopic Dermatitis
Who cites it
169 citing papers in PubMed, 297 citations in OpenAlex.
- Effect of Abrocitinib on the Skin Microbiome in Patients With Moderate-to-Severe Atopic Dermatitis.Allergy · 2026Trial
- CERS1 is a biomarker of Staphylococcus aureus abundance and atopic dermatitis severity.The Journal of allergy and clinical immunology · 2025Trial
- A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 16-Week Trial to Evaluate the Efficacy and Safety of FB-401 in Children, Adolescents, and Adult Subjects (Ages 2 Years and Older) with Mild-to-Moderate Atopic Dermatitis.Dermatology (Basel, Switzerland) · 2024Trial
- Rapid reduction in Staphylococcus aureus in atopic dermatitis subjects following dupilumab treatment.The Journal of allergy and clinical immunology · 2023Trial
- Antibacterial efficacy and mechanism of the novel antimicrobial peptide lachnospirin-1 againstVirulence · 2026Article
- Ceria-Based Nanotherapeutics for Inflammatory Skin Disorders: From Design and Mechanisms to Advanced Delivery and Future Perspectives.International journal of molecular sciences · 2026Review
- Repression of Virulence in Staphylococcus aureus by 2-Aminothiol-Mediated Quorum Quenching.Angewandte Chemie (International ed. in English) · 2026Article
- Occupational Contact Dermatitis in the Post-COVID Era: From Barrier Dysfunction and Microbiome Dysbiosis to Prevention and Precision Management.Journal of clinical medicine · 2026Review
- ABPs: diffusible antibacterial toxins secreted by and active against diverse gram-positive bacteria.Infection and immunity · 2026Review
- Skin Microbiome in Health and Disease: Dysbiosis and the Emerging Role of Biotics in Therapy and Protection.International journal of molecular sciences · 2026Review
- Taxonomic and Functional Skin Microbiome Profiles in Nummular Eczema, Atopic Dermatitis, and Mixed Phenotypes: An Exploratory Shotgun Metagenomic Pilot Study.Microorganisms · 2026Article
- An AI-augmented review of childhood atopic dermatitis biomarkers across genetic, immune, microbial, and metabolic domains.Molecular medicine (Cambridge, Mass.) · 2026Review
- Review
- Mass spectrometry-based metabolomics approaches to interrogate host-microbiome interactions in mammalian systems.Natural product reports · 2026Review
- Soluble bacterial lipopeptides suppress gasdermin D-associated IL-33 release in keratinocytes and atopic dermatitis in mice.Nature communications · 2026Article
- Microbial Dysbiosis in Photodermatoses: Formation, Pathogenesis and Intervention Strategies.Current issues in molecular biology · 2026Review
- Epithelial Barrier Dysfunction in Atopic Dermatitis, Allergic Contact Dermatitis, and Chronic Spontaneous Urticaria and its Therapeutic Implications.Current allergy and asthma reports · 2026Review
- Human and Marine Host Defense Peptides for Healthy Skin.Marine drugs · 2026Review
- Topical acacia gum reshapes staphylococcal dysbiosis and inflammation in atopic dermatitis.NPJ biofilms and microbiomes · 2026Article
- Dermal fibroblasts respond to IL-4 and IL-13 and promote T cell recruitment in atopic dermatitis.The Journal of clinical investigation · 2026Article
109 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 5 institutions in 1 country.
Funding
Abstract
Staphylococcus aureus colonizes patients with atopic dermatitis (AD) and exacerbates disease by promoting inflammation. The present study investigated the safety and mechanisms of action of Staphylococcus hominis A9 (ShA9), a bacterium isolated from healthy human skin, as a topical therapy for AD. ShA9 killed S. aureus on the skin of mice and inhibited expression of a toxin from S. aureus (psmα) that promotes inflammation. A first-in-human, phase 1, double-blinded, randomized 1-week trial of topical ShA9 or vehicle on the forearm skin of 54 adults with S. aureus-positive AD (NCT03151148) met its primary endpoint of safety, and participants receiving ShA9 had fewer adverse events associated with AD. Eczema severity was not significantly different when evaluated in all participants treated with ShA9 but a significant decrease in S. aureus and increased ShA9 DNA were seen and met secondary endpoints. Some S. aureus strains on participants were not directly killed by ShA9, but expression of mRNA for psmα was inhibited in all strains. Improvement in local eczema severity was suggested by post-hoc analysis of participants with S. aureus directly killed by ShA9. These observations demonstrate the safety and potential benefits of bacteriotherapy for AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.